Epidemiology of High-risk Biochemical Recurrence After Primary Prostate Cancer Treatment
HR-BCR incidence varies by definition and treatment. The EMBARK criteria identify a smaller subset with the highest PCSM risk. Many patients with BCR never develop HR-BCR. Refining BCR definitions with PSA kinetics and imaging may optimize risk stratification, balancing therapeutic efficacy and overtreatment.
Authors
- Giuseppe Carrieri (ORCID: https://orcid.org/0000-0002-6609-6434)
- Peter N. Wiklund (ORCID: https://orcid.org/0000-0001-6497-4697)
- Ugo Giovanni Falagario (ORCID: https://orcid.org/0000-0002-1152-3005)
- Henrik Grönberg (ORCID: https://orcid.org/0000-0002-1073-2753)
- Giorgio Gandaglia (ORCID: https://orcid.org/0000-0002-5052-721X)
- Tobias Nordström (ORCID: https://orcid.org/0000-0003-4915-7546)
- Alexander Valdman (ORCID: https://orcid.org/0000-0001-7281-0991)
- Ash Tewari (ORCID: https://orcid.org/0000-0003-0888-7585)
- Alberto Briganti (ORCID: https://orcid.org/0000-0002-2178-0494)
- Alberto Martini (ORCID: https://orcid.org/0000-0003-1272-7154)
- Francesco Pellegrino (ORCID: https://orcid.org/0000-0001-6126-0904)
- Anna Lantz (ORCID: https://orcid.org/0000-0002-5335-8028)
- Vincenza Conteduca (ORCID: https://orcid.org/0000-0002-6921-714X)
- Markus Aly (ORCID: https://orcid.org/0000-0002-7602-9198)
- Olof Akre (ORCID: https://orcid.org/0000-0002-3750-3029)
- Lars Björnebo (ORCID: https://orcid.org/0000-0002-5573-0794)
- Thorgerdur Palsdottir (ORCID: https://orcid.org/0000-0003-3491-3986)
- Martin Eklund (ORCID: https://orcid.org/0000-0001-5032-5266)
- Ahmad Abbadi (ORCID: https://orcid.org/0000-0001-9373-668X)
- Francesco Montorsi
Institutions
- University of Foggia (IT)
- The University of Texas MD Anderson Cancer Center (US)
- Karolinska Institutet (SE)
- Karolinska Development (Sweden) (SE)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- European Urology Oncology
- Published
- 2025-06-21
- DOI
- https://doi.org/10.1016/j.euo.2025.05.026
- Citations
- 3
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 4.56